A Phase 1/2 interventional study of TM5614 and Placebo in Covid19, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Northwestern University · Phase 1/2, Interventional, and Treatment
Enrollment challenges due to decline in COVID
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 1,156th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 62 in phase 1/2, and was the 806th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 7 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized double blind placebo controlled trial to evaluate the efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized with severe COVID-19 at Northwestern Memorial Hospital. The patients will be randomized in a 1:1 ratio to receive standard of care plus TM5614 or standard of care plus placebo.
This project will evaluate the efficacy and safety of a novel small molecule therapy targeting PAI-1 (TM5614) for patients with severe COVID-19. This is a randomized (1:1), double-blinded trial that will enroll adult patients (> 65 years OR \<65 years with at least one major cardiometabolic comorbidity [diabetes, hypertension, or cardiovascular disease]) with COVID-19 requiring supplemental oxygen. The study intervention will be a small molecule inhibitor of PAI-1, TM5614, up to 180 mg, compared to matching placebo for up to 7 days.
Research blood samples for PAI-1 and C-reactive protein (CRP) will be collected at time of enrollment, 48 hours after 1st dose of medication and at day 7 or discharge, whichever comes first.
These objectives will allow for the planning of subsequent phase 3 study, and strengthen implementation of a multi-center randomized trial should this study confirm safety, and suggest efficacy of therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known to tissue plasminogen activator (tPA), including
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days
Drug: TM5614
Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days
Other: Placebo
TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
Also known as: Plasminogen activator inhibitor-1 (PAI-1)
Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
Also known as: TM5614 Placebo
Clinical Improvement
Change of at least 2 points in the NIAID-defined ordinal scale (higher scores indicate improved outcome),: 1. Death 2. Hospitalized, receiving invasive mechanical ventilation or ECMO 3. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring low-flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19) 6. Hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol) 7. Not hospitalized
Time frame: 7 Days
Sequential Organ Failure Assessment (SOFA) Score Change
Change in degree of organ dysfunction as defined by the Sequential Organ Failure Assessment (SOFA) Score. The SOFA score ranges from 0 to 24 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 6 organ dysfunctions (ie, central nervous system, cardiovascular, respiratory, renal, coagulation, and liver).
Time frame: 7 Days
PAI-1 Levels
Change in circulating PAI-1 Levels (ng/mL) at discharge from baseline
Time frame: 48 hours
| Milestone | TM5614 | Placebo |
|---|---|---|
| Started | 4 | 4 |
| Completed | 4 | 4 |
| Not completed | 0 | 0 |
Change of at least 2 points in the NIAID-defined ordinal scale (higher scores indicate improved outcome),: 1. Death 2. Hospitalized, receiving invasive mechanical ventilation or ECMO 3. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring low-flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19) 6. Hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol) 7. Not hospitalized
| Participants | TM5614 | Placebo |
|---|---|---|
| Clinical Improvement | 3 | 1 |
Change in degree of organ dysfunction as defined by the Sequential Organ Failure Assessment (SOFA) Score. The SOFA score ranges from 0 to 24 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 6 organ dysfunctions (ie, central nervous system, cardiovascular, respiratory, renal, coagulation, and liver).
| Scores on a scale | TM5614 | Placebo |
|---|---|---|
| Sequential Organ Failure Assessment (SOFA) Score Change | 0 (-4 to 0) | 0 (-1 to 4) |
Change in circulating PAI-1 Levels (ng/mL) at discharge from baseline
| ng/mL | TM5614 | Placebo |
|---|---|---|
| PAI-1 Levels | 12.0 (6.1 to 14.1) | 21.0 (19.9 to 40.9) |
Collected over from enrollment until end of follow-up, up to 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TM5614 | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Placebo | 0/4 (0%) | 2/4 (50%) | 2/4 (50%) |
| Event | TM5614 | Placebo |
|---|---|---|
| HypotensionBlood and lymphatic system disorders | 0/4 | 1/4 |
| HypoxemiaRespiratory, thoracic and mediastinal disorders | 0/4 | 1/4 |
| Event | TM5614 | Placebo |
|---|---|---|
| EpistaxisGastrointestinal disorders | 0/4 | 1/4 |
| Elevated bicarbonate levelBlood and lymphatic system disorders | 0/4 | 1/4 |
| LeukocytosisBlood and lymphatic system disorders | 0/4 | 1/4 |
| Mechanical fallMusculoskeletal and connective tissue disorders | 0/4 | 1/4 |
| BleedingBlood and lymphatic system disorders | 0/4 | 1/4 |
| Age, Categorical(Participants) | TM5614 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 4 | 7 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | TM5614 | Placebo | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | TM5614 | Placebo | Total |
|---|---|---|---|
| White | 1 | 2 | 3 |
| Black | 0 | 1 | 1 |
| Hispanic | 3 | 1 | 4 |
| Region of Enrollment(Participants) | TM5614 | Placebo | Total |
|---|---|---|---|
| United States | 4 | 4 | 8 |
| PAI-1 Activity at Baseline(ng/mL) | TM5614 | Placebo | Total |
|---|---|---|---|
| Median | 60.4 (26.3 to 73.2) | 17.7 (4.6 to 38.9) | 26.3 (4.6 to 73.2) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2021 to primary completion in May 2021, 4 months.
Results were first posted in Sep 2026, 5 years 4 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Apr 2025 → May 2021 and completion May 2025 → Aug 2021.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Enrollment challenges due to decline in COVID
Enrollment challenges due to decline in COVID
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.